Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 20, 2017 09:00 ET | Source: Stemline Therapeutics

Stemline Therapeutics Prices $45 Million Public Offering of Common Stock

NEW YORK, Jan. 20, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced the pricing...
January 19, 2017 16:03 ET | Source: Stemline Therapeutics

Stemline Therapeutics Announces Proposed Public Offering of Common Stock

NEW YORK, Jan. 19, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, today announced that it...
January 09, 2017 17:15 ET | Source: Stemline Therapeutics

Stemline Therapeutics Announces Date Change for the Company’s Presentation at the 35th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline’s CEO, will now present at the 35th Annual J.P. Morgan...
January 09, 2017 10:30 ET | Source: Stemline Therapeutics

Stemline Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference

NEW YORK, Jan. 09, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline’s CEO, will present at the 35th Annual J.P. Morgan...
January 05, 2017 16:30 ET | Source: Stemline Therapeutics

Stemline Therapeutics Announces Positive FDA Meeting and Agreement on Expedited Pathway to Full Approval of SL-401 in First-Line BPDCN

Ongoing Phase 2 trial with additional small cohort (8-12 patients planned) sufficient for BLA filing for full approval Approximately half of new cohort patients already enrolled, with full enrollment...
December 06, 2016 11:48 ET | Source: Stemline Therapeutics

Stemline Therapeutics Presents SL-401 Lead-in Results from its Ongoing Phase 2 Trial in AML in Remission with MRD and Phase 2 Trial in High-Risk Myeloproliferative Neoplasms (MPN) at ASH

NEW YORK, Dec. 06, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the presentation of SL-401 lead-in data from its ongoing Phase 2 trial in acute myeloid leukemia...
December 05, 2016 12:48 ET | Source: Stemline Therapeutics

Stemline Therapeutics’ SL-401 Phase 2 BPDCN Data Delivered Via Oral Presentation at ASH; High Response Rates Maintained Across All Lines

NEW YORK, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the oral presentation of positive clinical data from its ongoing SL-401 Phase 2 potentially...
December 02, 2016 07:30 ET | Source: Stemline Therapeutics

Stemline Announces Seven Presentations, Including Oral Presentation of Updated SL-401 Phase 2 BPDCN Data, at the 2016 ASH Meeting this Weekend

NEW YORK, Dec. 02, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that SL-401, a novel targeted therapeutic directed to CD123, will be featured in seven...
November 21, 2016 07:30 ET | Source: Stemline Therapeutics

Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 21st Annual Meeting of the Society of Neuro-Oncology (SNO)

NEW YORK, Nov. 21, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today the oral presentation of clinical data from its ongoing Phase 2 trial of SL-701 in patients...
November 08, 2016 07:00 ET | Source: Stemline Therapeutics

Stemline Therapeutics Reports Third Quarter 2016 Financial Results and Highlights Recent Regulatory and Clinical Progress

NEW YORK, Nov. 08, 2016 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) today reported financial results for the quarter ended September 30, 2016.Ivan Bergstein, M.D., Stemline’s Chief...